Xofigo

Not for use in females. Bone marrow suppression. Perform hematologic evaluation at baseline and prior to every dose. Before 1^st dose, the ANC should be ≥1.5×10⁹/L, platelets ≥100×10⁹/L and hemoglobin ≥10g/dL. Before subsequent doses, the ANC should be ≥1×10⁹/L and platelets ≥50×10⁹/L; discontinue if no recovery within 6–8 weeks after last dose despite receiving supportive care. Monitor closely if evidence of compromised bone marrow reserve. Discontinue if life-threatening complications occur despite supportive care for bone marrow failure. Monitor oral intake and fluid status carefully. Embryo-fetal toxicity. Advise males (use condoms) and female partners of reproductive potential to use effective contraception during and 6 months after completion. Pregnancy. Nursing mothers: not studied.